Predict your next investment

HEALTHCARE | Biotechnology
neuroderm.com

See what CB Insights has to offer

Founded Year

2003

Stage

Acq - P2P | Acquired

Total Raised

$20.5M

Valuation

$0000 

About NeuroDerm

NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. In Parkinson's disease, the company has four product candidates in different stages of development which offer a solution for almost every Parkinson's disease patient from the moderate to the very severe stage of the disease. The company has developed a line of LD/CD product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD line of product candidates includes: ND0612L and ND0612H, delivered subcutaneously, for moderate and for advanced Parkinson's disease patients, respectively, and ND0680 for a subset of severe Parkinson's disease patients whose symptoms have advanced to a more acute stage, requiring even higher doses of LD/CD. In addition NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from severe Parkinson's disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park, Rehovot, Israel.

NeuroDerm Headquarter Location

3 Pekeris Street, Ruhrberg Science Bldg Bell Entrance, Rabin Science Park

Rehovot, 7670212,

Israel

+972-8-9462729

Latest NeuroDerm News

Bimekizumab shows rapid, effective treatment of plaque psoriasis

Feb 10, 2021

Disclosures: Lebwohl reports he is an employee of Mount Sinai Hospital, which receives research funds from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant, Eli Lilly, Incyte, Janssen Research & Development, Leo Pharma, Ortho Dermatologics, Pfizer and UCB Pharma, and is a consultant for Aditum Bio, Allergan, Almirall, Arcutis, Avotres Therapeutics, BirchBioMed, BMD Skincare, Boehringer Ingelheim, BMS, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, Leo Pharma, Meiji Seika Pharma, Menlo, Mitsubishi, NeuroDerm, Pfizer, Promius/Dr Reddy’s Laboratories, Serono, Theravance and Verrica. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio A phase 3 study found bimekizumab to be more efficacious in the treatment of plaque psoriasis than both ustekinumab and placebo. “Bimekizumab differs from other [interleukin] drugs currently available in that it blocks two molecules, IL-17A and IL-17F,” Mark Lebwohl, MD, one of the study’s authors and Waldman Chair of Dermatology at the Icahn School of Medicine at Mount Sinai, told Healio. “There’s a big overlap between those molecules in the body. ... One of the things they do is they cause psoriasis.” Bimekizumab was more efficacious than ustekinumab and placebo in the treatment of moderate to severe plaque psoriasis. The multicenter, randomized, double-blind, active-comparator, placebo-controlled BE VIVID trial included 567 patients and took place at 105 locations across 11 countries. Mark Lebwohl Subjects were randomly assigned 4:2:1 to receive bimekizumab 320 mg every 4 weeks , ustekinumab 45 mg or 90 mg (weight-dependent dosing) at weeks 0 and 4 and then every 12 weeks, or placebo every 4 weeks. Evaluations were conducted at weeks 1, 2 and 4 and then every 4 weeks through week 52. At week 16, 85% of those in the bimekizumab group had a 90% improvement in Psoriasis Area Severity Index score compared with 50% in the ustekinumab group and 5% in the placebo group (both P < .0001). PASI 100 was observed in 59% of subjects in the bimekizumab group at week 16 compared with 21% in the ustekinumab group and 0% in the placebo group (both P < .0001). “To this day, we have never before had a drug that at the end of the placebo-control period of a study has a majority of patients achieving PASI 100, meaning not a dot of psoriasis left,” Lebwohl said. At week 52, 82% of bimekizumab subjects still had a score of PASI 90 compared with 56% of ustekinumab subjects and 0% of placebo subjects. Investigator’s Global Assessment response was also greater at all time points for bimekizumab than either ustekinumab or placebo. In addition, the speed of bimekizumab’s effectiveness was noted. “This drug was incredibly fast. At week 4, 76.9% of patients achieved PASI 75,” Lebwohl said. “The magnitude of the response and the speed of the response beat everything else we have. This gives us a drug that is safe, effective and works to a degree we haven’t seen before. It gives us yet another option to improve the effectiveness of the current armamentarium of psoriasis that we have.” Perspective Jerry Bagel, MD, MS Ustekinumab became FDA approved for the treatment of psoriasis in September 2009, dosed at 45 mg for patients less than 100 kg and 90 mg for patients more than 100 kg, with dosing at 0 and 4 weeks and then every 12 weeks. It has a 12-week PASI 75 response rate of 70% and PASI 90 response rate of 41%, with a relatively good safety profile compared with TNF inhibitor. This resulted in Stelara (ustekinumab, Janssen Biotech) becoming a favorite biologic agent for the treatment of psoriasis. From a practical perspective, the question is, what do patients want? They want to be clear, and they do not want to do anything about it. Well, here is Stelara. Four shots a year, and 40% of patients with very little residual psoriasis. They do not have to think about their skin except for 4 days a year. And even more so, no black box warnings. It does not seem to have increased risk for opportunistic infections, demyelinating diseases, inflammatory bowel disease or congestive heart failure. Although Stelara’s risk-benefit ratio has remained favorable over the past decade, a new cadre of biologic agents has entered the psoriatic therapeutic armamentarium. The IL-17 and IL-23 monoclonal antibodies have exhibited a higher efficacy. The PASI 90 has in some cases approached 85%, not only at 12 weeks or 16 weeks, but maintained through week 52 and in some studies through 5 years. PASI 100 has been exhibited in more than 50% at week 16 through 5 years. The BE VIVID study compares the efficacy and safety of bimekizumab vs. ustekinumab from a 52-week, multicenter, double-blind, active-comparator, placebo-controlled phase 3 trial. Bimekizumab is mechanistically unique in that it binds both IL-17A and IL-17F as opposed to just IL-17A, such as in Taltz (ixekizumab, Eli Lilly and Company), Cosentyx (secukinumab, Novartis) and Siliq (brodalumab, Bausch Health). The baseline demographics of the ustekinumab and bimekizumab groups were similar, equally regionally distributed through Asia, Australia, Europe and North America. Disease duration was 18 years, baseline PASI was 22, body surface area was 28%, and 39% were on previous biologic therapy. The data clearly reveal that bimekizumab at week 16 showed PASI 90, PASI 100 and DLQI 0/1 at 85%, 59% and 67%, respectively. Ustekinumab’s 16-week data showed PASI90 in 50%, PASI 100 in 21% and DLQI 0.1 in 42%. At week 52, PASI 90 for bimekizumab was 82%, while ustekinumab was 56%. Remarkably week 4 PASI 75 for bimekizumab was 77%, while ustekinumab was 15%. In practical terms, to start with PASI 22 and after only one dose of bimekizumab and 4 weeks, three-quarters of all patients PASI dropped to 5 or less is fast. This is compared with less than 20% of those on ustekinumab. Patients want fast. Patients want high efficacy. I see patients choosing rapid onset and higher long-term efficacy over fewer shots. The safety profile between the two medications is similar except for an increased frequency of mild Candida infections on bimekizumab. Bimekizumab appears to be a very effective, relatively safe biologic therapy that shows better efficacy than ustekinumab. I am sure it will be utilized often in the treatment of psoriasis. I would like to see a head-to-head study between bimekizumab and either guselkumab or risankizumab. Jerry Bagel, MD, MS Psoriasis Treatment Center of Central New Jersey Disclosures: Bagel reports he has received research funds payable to Psoriasis Treatment Center from AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Corrona, Dermavant Sciences, LTD, Dermira, UCB, Eli Lilly and Company, Glenmark Pharmaceuticals, Janssen Biotech, Kadmon, Leo Pharma, Lycera, Menlo Therapeutics, Novartis, Pfizer, Regeneron Pharmaceuticals, Sun Pharma, Taro Pharmaceutical Industries and Ortho Dermatologics; consultant fees from AbbVie, Amgen, Celgene, Bristol-Myers Squibb, Eli Lilly and Company, Janssen Biotech, Novartis, Sun Pharmaceutical Industries and UCB; and fees for speaking from AbbVie, Celgene, Eli Lilly, Janssen Biotech and Novartis. Read more about:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing NeuroDerm

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NeuroDerm is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

NeuroDerm Patents

NeuroDerm has filed 48 patents.

The 3 most popular patent topics include:

  • Monoamine oxidase inhibitors
  • Neurological disorders
  • Graphical projections
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/5/2018

6/1/2021

Graphical projections, Technical drawing, Light machine guns, Roadsters, Cephalopod zootomy

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/5/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/1/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Graphical projections, Technical drawing, Light machine guns, Roadsters, Cephalopod zootomy

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.